Syndax Pharmaceuticals (SNDX) Non-Current Deffered Revenue (2015 - 2021)

Syndax Pharmaceuticals' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $10.9 million for Q2 2021.

• In Q2 2021, Non-Current Deffered Revenue fell 12.25% year-over-year to $10.9 million; the TTM figure through Jun 2021 stood at $10.9 million (down 12.25% YoY), while the FY2020 annual figure was $11.6 million, down 11.54% from the prior year.
• Non-Current Deffered Revenue was $10.9 million for Q2 2021 at Syndax Pharmaceuticals, down from $11.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $16.8 million in Q4 2017 to a low of $10.9 million in Q2 2021.
• Historically, Non-Current Deffered Revenue has averaged $13.6 million across 5 years, with a median of $13.6 million in 2017.
• The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue advanced 17.86% in 2017, then decreased 12.58% in 2018.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $16.8 million in 2017, then slipped by 12.58% to $14.6 million in 2018, then retreated by 10.35% to $13.1 million in 2019, then decreased by 11.54% to $11.6 million in 2020, then decreased by 6.52% to $10.9 million in 2021.
• The last three Non-Current Deffered Revenue figures came in at $10.9 million (Q2 2021), $11.2 million (Q1 2021), and $11.6 million (Q4 2020), per Business Quant data.